DXCM vs. MMM, RMD, BAX, PODD, TFX, NVCR, BSX, WST, EW, and COR
Should you be buying DexCom stock or one of its competitors? The main competitors of DexCom include 3M (MMM), ResMed (RMD), Baxter International (BAX), Insulet (PODD), Teleflex (TFX), NovoCure (NVCR), Boston Scientific (BSX), West Pharmaceutical Services (WST), Edwards Lifesciences (EW), and Cencora (COR).
3M (NYSE:MMM) and DexCom (NASDAQ:DXCM) are both large-cap multi-sector conglomerates companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
In the previous week, 3M had 6 more articles in the media than DexCom. MarketBeat recorded 21 mentions for 3M and 15 mentions for DexCom. 3M's average media sentiment score of 0.76 beat DexCom's score of 0.64 indicating that DexCom is being referred to more favorably in the news media.
DexCom received 66 more outperform votes than 3M when rated by MarketBeat users. Likewise, 71.94% of users gave DexCom an outperform vote while only 59.46% of users gave 3M an outperform vote.
3M has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
3M currently has a consensus price target of $104.00, suggesting a potential upside of 13.80%. DexCom has a consensus price target of $141.40, suggesting a potential upside of 3.63%. Given DexCom's higher possible upside, equities analysts clearly believe 3M is more favorable than DexCom.
65.3% of 3M shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.3% of 3M shares are owned by company insiders. Comparatively, 0.4% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
DexCom has lower revenue, but higher earnings than 3M. 3M is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
DexCom has a net margin of 14.95% compared to DexCom's net margin of -21.40%. DexCom's return on equity of 62.45% beat 3M's return on equity.
Summary
DexCom beats 3M on 14 of the 19 factors compared between the two stocks.
Get DexCom News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
